SPAC Voyager Acquisition II files for a $220 million IPO, targeting tech, fintech, and healthcare
IPO Overview
Voyager Acquisition II, a blank check company targeting technology, fintech, and healthcare, filed on Friday with the SEC to raise up to $220 million in an initial public offering.
The company plans to raise $220 million by offering 22 million units at a price of $10. Each unit consists of one share of common stock and one-half of one warrant, exercisable at $11.50.
Voyager Acquisition II is led by CEO Adeel Rouf, who previously served as an investment professional at Cohen and Company Asset Management. He is joined by CFO Alex Rogers, who has been a member of the investment team and manages investor relations and communications at Blue Ox Healthcare Partners, and Chairman Warren Hosseinion, the Chairman of Cardio Diagnostics, previous CEO and Director of Clinigence Holdings, and co-founder of Apollo Medical Holdings. The SPAC intends to target businesses in the technology, financial technology, and healthcare industries.
Management’s previous SPAC, Voyager Acquisition （VACH; +10% from $10 offer price）， has a pending merger agreement with Swiss oncology biotech VERAXA.
The Brooklyn, NY-based company was founded in 2024. It plans to list on the Nasdaq under the symbol VAIIU. Voyager Acquisition II filed confidentially on January 27, 2025. Cantor Fitzgerald is the sole bookrunner on the deal.
About the Company
Voyager Acquisition Corp. II （formerly known as Explorer Acquisition Corp） is a blank check company incorporated as a Cayman Islands exempted company and incorporated for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities, which we refer to throughout this prospectus as our initial business combination. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, initiated any substantive discussions, directly or indirectly, with any business combination target. We may pursue an initial business combination in any business or industry but expect to target opportunities and companies that are in the technology, financial technology （“fintech”）， and healthcare industries.
